BioCentury This Week
चैनल विवरण
BioCentury This Week
BioCentury's streaming commentary on biotech industry trends, plus interviews with KOLs.For three decades, BioCentury has helped biopharma executives and investors make business-critical decisions and build larger networks with peers across the innovation ecosystem.
हाल के एपिसोड
337 एपिसोड
Ep. 327 - Where Gene & Cell Therapy Go Next With Evotec's Bernd Mühlenweg
It’s been a tough year for cell and gene therapy — patient deaths, high-profile companies pulling out of the space, and sour investment sentiment. But...
Ep. 326 - Market Outlook, Biosecure Returns, Biotech M&A
Biotech’s fourth quarter began with a familiar feeling, with indicators pointing toward an improving public market even as political and regulatory un...
Ep. 325 - Pfizer MFN Deal, New Trial Paradigm & Billion $ Fund
The short-term consequences for Pfizer from its “most favored nation” drug pricing deal with the White House are negligible, but the long-term effects...
Ep. 324 - Genmab, GSK and Drug Pricing
Genmab's $8 billion acquisition of multispecifics company Merus is the Danish biotech’s largest step toward marketing its own pipeline. On the latest...
Ep. 323 - Agentic AI: From New Targets to the Clinic
AI is bringing sweeping changes to drug development, from how targets are discovered to optimizing clinical trials to maximize an asset’s chance for s...
Ep. 322 - Takeaways from BioCentury Grand Rounds Europe
Is this the U.K.’s moment to capitalize on its biotech ecosystem? That was one of the primary themes discussed at the debut Grand Rounds — Europe conf...
Ep. 321 - Pfizer’s Obesity Play & U.K. in Focus
A takeout that could be worth as much as $7.3 billion has Pfizer back in the obesity drug development race. On the latest BioCentury This Week podcast...
Ep. 320 - U.K. Biotech, U.S.-China, Insmed
Merck's announcement that it is moving its R&D out of the U.K. highlights concerns about the country’s life sciences policies. On the latest BioCentur...
Ep. 319 - David Baltimore’s Legacy, Atlas Fund, MASH Pipeline and more
Molecular biologist and Nobel Prize winner David Baltimore made foundational contributions to the biopharma industry and was the essential figure behi...
Ep. 318 - Newco Takes on CV Risk. Plus: Disrupting Vaccines
Two veteran biotech leaders are launching a new company with ambitions in the cardiovascular disease space. On the latest BioCentury This Week podcast...
Ep. 317 - Biotech IPOs, FDA-Stealth & Patent Threat
There’s been a rare IPO filing on NASDAQ as LB Pharma looks to test the market during a year that has seen little activity among U.S. biotechs even as...
Ep. 316 - Trends in Pharma Deals
BioCentury’s third annual analysis of pharma company deals finds that bispecifics and degraders are in, cell and gene therapies are out, and China is...
Ep. 315 - China Speed: Data, Deals, First in Class
Dealmaking between Western and Chinese biopharmas has been one of the year’s bright spots, as a maturing biotech landscape in China converges with Wes...
Ep. 314 - Prasad, Lilly Obesity, Acadia & Biosecure
Phase III data from Lilly’s orforglipron in obesity fell short of investor expectations, but they appear to be enough to obtain approval and wide use....
Ep. 313 - Lessons from FDA's Prasad. Plus: What's next for Novo, Bayer
The ouster of Vinay Prasad after three months running FDA’s Center for Biologics Evaluation and Research could signal a reset is ahead for CBER. On th...
Ep. 312 - Biotech Progress Report
A handful of encouraging signals is cause for cautious optimism for biotech headed into the second half of the year — companies have been able to parl...
Ep. 311 - The Asia Deals Landscape, U.K. Biotech & More
This week’s deal between GSK and Jiangsu Hengrui is a prime example of how Western biopharmas have begun to recognize the innovation and opportunities...
Ep. 310 - Sarepta & What's Next for Gene Therapy. Plus: Leading FDA's CDER
Last week’s public disclosure that a gene therapy from Sarepta had caused a third death led FDA to ask the company to stop distributing its DMD gene t...
Ep. 309 - 3Q Markets Preview; Quantum Computing; Makary’s First 100 Days
Chinese biotech is the lone bright spot for the biopharma financial markets in 1H25, as macro concerns about the most favored nation (MFN) pricing pol...
Ep. 308 - Grand Rounds - Europe Preview
There are many reasons why it may be the European biomedical ecosystem’s moment to shine, and advances at the academia-industry interface are a core p...
Ep. 307 - How Cancer Regulation is — and isn’t — Changing at FDA
Oncology regulation has been less affected by recent changes in FDA leadership than other parts of the agency. On a special sponsored edition of the B...
Ep. 306 - Treg Inflection Point; Biotech's Next Big Story; Tax Bill Consequences
Treg-based cell therapies are nearing a clinical proof-of-concept inflection point, but in an environment that has dramatically shifted with the adven...
Ep. 305 - FDA's Future; In Vivo CAR T Plays; Psychedelics; CDK2
The Trump administration’s overhaul of FDA is still underway, but the agency has already veered away from its decades-long trajectory in ways that wil...
Ep. 304 - Syncona Reshapes Fund; Lilly's $1B Verve Bet; FDA's 2-Track Future
Publicly traded U.K. investment firm and company builder Syncona is restructuring its fund amid ongoing market challenges in the biopharma industry. O...
Ep. 303 - Gene Therapy Safety, Amylin in Obesity & FDA's Future
The tragic death of a second non-ambulatory DMD patient treated with Sarepta's Elevidys gene therapy marks a turning point for the field and should dr...
Ep. 302 - Takeaways from BioCentury Grand Rounds Chicago
With federal funding at risk and VCs increasingly focused on de-risked assets, academia is facing unprecedented headwinds despite rapid advancements i...
Ep. 301 - ASCO’s First-in-Human Trials, Crossover Investors & FDA's Rare Disease Plans
Translational trends at this year’s ASCO meeting featured new and selective ways to target cell surface receptors on solid tumors. On the latest BioCe...
Ep. 300 - Biotech’s $13B Deal Day, ASCO's Hot Targets, Drug Pricing Threat
Dealmaking by a pair of pharmas has given the biotech industry its best day of transactions in months, tallying nearly $13 billion in guaranteed payme...
Ep. 299 - ASCO, EpCAM, Rocket & HK IPOs
Dutch biotech Merus’ EGFR x LGR5 bispecific antibody has caught investors’ attention in the run-up to ASCO as a new approach to block EGFR signaling....
Ep. 298 - Takeaways from the 25th Bio€quity Europe
Political and market turmoil has raised questions whether the U.S. can retain its biopharma leadership position, and in turn presents Europe with an o...
Ep. 297 - European Biotech's Moment? Plus: Biomarin, Boston Deals & Novo Nordisk CEO
The turbulence that has come with the Trump administration’s policies related to the U.S. biopharmaceutical industry is creating an opening for Europe...
Ep. 296 - Trends in Obesity, Vinay Prasad at FDA, Ovarian Cancer Insights
Biopharmas developing therapies for obesity are looking to a future where the quality of weight loss matters as much as the quantity — what targets an...
Ep. 295 - Bio€quity Europe 2025 Preview
This year’s Bio€quity Europe conference — the 25th edition of the event — will focus on what’s next for Europe amid biotech’s current complex moment,...
Ep. 294 - AACR Spotlight on SMARCA2 degraders. Plus: David Baker, Drug Pricing
Among the formerly undruggable targets gaining translational momentum, SMARCA2 has intrigued researchers for its potential to treat challenging solid...
Ep. 293 - Tau Time for Alzheimer's. Plus: FDA Delays, Merck's $4B Deal, HK IPOs
Belief in tau — both as a target and surrogate endpoint — for Alzheimer’s is building among leaders in the field. On the latest BioCentury This Week p...
Ep. 292 - Myasthenia Gravis Spotlight & AACR Preview
Biopharma companies are vying to dethrone Vyvgart as a leading therapy for myasthenia gravis, with the latest data for therapies treating the rare aut...
Ep. 291 - Grand Rounds - U.S. Preview
The academia-industry interface is more important than ever for sustaining biomedical innovation’s forward momentum, even as the Trump administration...
Ep. 290 - Biotech Survey Sees Tough Days Ahead. Plus: FDA, China Speed
The biotech community is reeling, fearful and furious about the fallout of tariff, FDA and NIH policies, according to BioCentury’s newly released Risk...
Ep. 289 - Replacing Animal Models. Plus: RFK Jr. & FDA
FDA’s plan to move away from animal toxicity testing could expedite INDs and cut costs for biopharma companies, while helping the U.S. maintain its po...
Ep. 288 - FDA and Tariffs Turmoil, and AACR Preview
Loss of leadership, cuts to staffing and a proposed reorganization at FDA have heightened biotech risk amid an already turbulent macroeconomic climate...